Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.72 |
| ▸ | THRA | P10827 | 11/20 | 0.66 |
| ▸ | THRB | P10828 | 11/20 | 0.66 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | ASPH | Q12797 | 1/20 | 0.66 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.66 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.66 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781574 | 0.96 | THRA (0.72) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL1656106 | 0.88 | EGLN1 (0.59) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL1219877 | 0.86 | EGLN1 (0.69) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL16841133 | 0.84 | EGLN1 (0.88) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL522741 | 0.84 | EGLN1 (1.00) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL522900 | 0.83 | EGLN1 (1.00) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL27735218 | 0.83 | TDP1 (0.51) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL15547320 | 0.82 | EGLN1 (0.94) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL523036 | 0.82 | EGLN1 (0.84) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL3789365 | 0.80 | THRA (0.88) | EGLN1THRATHRBBBOX1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331362-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331362-A1 | Treatment method for anemia | THPO, EPOR, MPL | EGLN1 85/4885THRA 247/4885THRB 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.